Mesothelioma advocates around the country are expressing concern about a proposed rule from the federal Office of Management and Budget. If approved, the new rule could fundamentally change how federally funded scientific research is evaluated and continued, and significantly change the independent peer-review process. Historically, that process has driven every meaningful advance in mesothelioma treatment, and experts fear that changing it will put both ongoing clinical trials and international collaborations at risk.
Mesothelioma Research Faces Threat from Override of Scientific Peer Review
For decades, federal grants for research into mesothelioma and thousands of other medical conditions have been awarded through a competitive peer review process in which scientists evaluate proposals based on merit, innovation, and potential patient impact. Under the proposed rule, independent scientific experts would no longer be the final authority on which research receives federal funding. Instead, the proposed rule would allow political appointees to override scientific recommendations. Where decisions have historically been guided solely by evidence, this new dynamic could introduce priorities unrelated to patient need or scientific promise.
Of immediate concern to mesothelioma patients already enrolled in ongoing studies, federally funded research projects in process could be terminated if the appointees decide that they are “inconsistent with program goals or agency priorities.” This means that clinical trials could be halted mid-study, even after patients have enrolled and researchers have invested years of work. For mesothelioma patients participating in trials that represent their best remaining treatment option, the possibility of a sudden politically motivated termination is deeply alarming.
International Collaboration in Mesothelioma Research is Invaluable
Mesothelioma is one of the rarest and most challenging cancers to study, and funding for research has always been limited by the emphasis on more common malignancies and conditions. Because the disease is so rare, researchers regularly collaborate globally to enroll enough patients for clinical trials to be meaningful. They also share tissue samples and data with international research centers. The proposed role would also introduce significant restrictions on international scientific collaboration. Without partnerships with research centers across the world, research progress could slow dramatically—delaying the new treatments patients desperately need.
Government Invites Commentary from Mesothelioma Community Until July 13
The Office of Management and Budget is accepting public comments on the proposed rule, allowing mesothelioma patients, families, caregivers, and advocates to submit personalized comments before a deadline of July 13. Comments describing personal experience are invaluable, including on how research, clinical trials, or international collaboration matters to you directly.
Advocates say that finding a cure for mesothelioma depends on stable federal research funding and that independent peer review ensures grants are awarded on scientific merit. They also say that patients in ongoing studies should not face politically motivated terminations and that international collaboration is essential, because no single country has enough mesothelioma patients to answer many critical research questions. If you would like to have your voice heard, you can submit your comment at https://federalregister.gov/documents/2026/05/29/2026-10817/regulation-for-federal-financial-assistance before the July 13 deadline.
If you or someone you love has been diagnosed with mesothelioma and you need access to resources, contact the Patient Advocates at Mesothelioma.net today.
